

Hanoi, April 02, 2026

INFORMATION DISCLOSURE

To: - State Securities Commission

- Hanoi Stock Exchange

1. Company Name: MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

- Stock Code: MED

- Address: No. 358, Giai Phong Road, Hoang Liet Ward, Thanh Xuan District, Ha Noi City.

- Person Responsible for Information Disclosure: Mr Mai Nhat Thanh

Type of information disclosure: Periodic ☒ Extraordinary As required

2. Information Disclosure Contents:

Measures and roadmap to address the situation of securities being under control.

3. This information was disclosed on the Company's website on April 2, 2026 at the following link: <http://www.mediplantex.com/vi/thong-tin-co-dong.html>

We hereby undertake that the above disclosed information is true and accurate, and we take full responsibility before the law for the content of the information disclosed.

**MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**

General Director



Mai Nhat Thanh

**MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness

No.: 08/2026/CV-MED

Hanoi, April 02, 2026

**To: - State Securities Commission
- Hanoi Stock Exchange**

Company Name: Mediplantex National Pharmaceutical Joint Stock Company

Address: 358 Giai Phong Street, Phuong Liet Ward, Hanoi City, Vietnam.

Tax Identification Number: 0100108430

Person Responsible for Information Disclosure: Mai Nhat Thanh

Position: General Director

Pursuant to Decision No. 192/QĐ/SGDHN dated March 18, 2026 issued by the Hanoi Stock Exchange regarding the placement of MED shares under warning status due to the auditor's "qualified opinion" on the 2025 financial statements of Mediplantex National Pharmaceutical Joint Stock Company (stock ticker: MED), the Company hereby respectfully provides the following explanation:

1. Reasons for the Qualified Audit Opinion

The qualified audit opinion relates to two Business Cooperation Contracts (BCCs):

- Contract No. 68/HĐHTKD dated June 1, 2017
- Contract No. 35/2009/HĐHT dated December 25, 2009

At present, the above Business Cooperation Contracts are under review, with the Company working with relevant parties and competent state authorities regarding their legal status, implementation plans, determination of rights and obligations, and financial statement recognition. Therefore, during the 2025 financial reporting period, the Company did not have sufficient documentation and basis to provide detailed information to the auditor, leading to the issuance of a "qualified opinion" by the audit firm.

2. Remedial Measures and Implementation Roadmap

In order to remedy the situation of the Company's securities being placed under warning status and to ensure compliance with information disclosure obligations, the Company commits to implementing the following measures:



- Expedite working with relevant partners to collect and complete legal documentation, implementation materials, and related reports concerning the two Business Cooperation Contracts (BCCs) mentioned above.
- Closely coordinate with relevant state authorities to ensure transparency and completeness in terms of legal and financial matters.
- Re-engage with the audit firm upon obtaining sufficient information to reconfirm the relevant matters.
- Update the remediation progress in the audited 2026 financial statements.

The Company commits to fully and promptly disclose information in compliance with the prevailing regulations on securities and corporate governance of public companies.

We respectfully request the State Securities Commission and the Hanoi Stock Exchange to consider and facilitate the Company in completing the remediation process as soon as possible.

Sincerely!

Recipients:

- As above
- Archived: Office

**MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**

General Director



Mai Nhat Thanh

